Omega-3 fatty acids for the treatment of depressive disorders in children and adolescents: a meta-analysis of randomized placebo-controlled trials
- PMID: 31534476
- PMCID: PMC6744624
- DOI: 10.1186/s13034-019-0296-x
Omega-3 fatty acids for the treatment of depressive disorders in children and adolescents: a meta-analysis of randomized placebo-controlled trials
Abstract
Background: To investigate the efficacy and safety of omega-3 fatty acids (O3FA) in treating depressive disorders in children and adolescents.
Method: We conducted a comprehensive search in electronic databases and hand-searched articles included for relevant studies. We included randomized controlled trials which studied on O3FA for treatment of children and adolescents with depression. The standard mean differences (SMDs) and the odds ratios (ORs) with 95% confidence intervals (CIs) were estimated by a random-effects model. The primary outcomes were end-point depressive symptoms scores (efficacy) and all-cause discontinuation (safety). The secondary outcome of response rate was also assessed. Subgroup analyses were performed by age, severity of depression and dosage. Risk of bias assessment was performed based on the Jadad score and the Cochrane Collaboration's risk-of-bias method.
Results: A total of four studies with 153 participants were included. In terms of efficacy, there was no significant difference of end-point depressive symptoms scores between O3FA and placebo (SMD = - 0.12, 95% CI - 0.53 to 0.30, P = 0.58; I 2= 30%). In terms of safety, the all-cause discontinuation showed no statistical significance between O3FA and placebo (OR = 1.3, 95% CI 0.58 to 2.93, P = 0.53; I 2= 0%). The response rate of O3FA was also not significant better than that of placebo (OR = 1.57, 95% CI 0.26 to 9.39, P = 0.62; I 2= 71%). Besides, there were also no significant differences in those subgroup analyses outcomes. The risk of bias of included trials were not high.
Conclusions: Only considering the limited evidence of O3FA in the acute treatment of major depressive disorder, it did not seem to offer a clear advantage for children and adolescents.
Keywords: Depression; Meta-analysis; Omega-3 fatty acids; Pediatric.
Conflict of interest statement
Competing interestsThe authors declare that they have no competing interests.
Figures
Similar articles
-
A Double-Blind Placebo-Controlled Trial of Omega-3 Fatty Acids as a Monotherapy for Adolescent Depression.J Clin Psychiatry. 2018 Jun 26;79(4):17m11596. doi: 10.4088/JCP.17m11596. J Clin Psychiatry. 2018. PMID: 29985566 Free PMC article. Clinical Trial.
-
A double-blind, placebo-controlled trial of ω-3 fatty acids in Tourette's disorder.Pediatrics. 2012 Jun;129(6):e1493-500. doi: 10.1542/peds.2011-3384. Epub 2012 May 14. Pediatrics. 2012. PMID: 22585765 Free PMC article. Clinical Trial.
-
Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.Cochrane Database Syst Rev. 2021 Jan 18;1(1):CD013011. doi: 10.1002/14651858.CD013011.pub2. Cochrane Database Syst Rev. 2021. PMID: 33460048 Free PMC article.
-
Antidepressants for people with epilepsy and depression.Cochrane Database Syst Rev. 2021 Apr 16;4(4):CD010682. doi: 10.1002/14651858.CD010682.pub3. Cochrane Database Syst Rev. 2021. PMID: 33860531 Free PMC article.
-
ω-3 fatty acids therapy for IgA nephropathy: a meta-analysis of randomized controlled trials.Clin Nephrol. 2012 Feb;77(2):119-25. doi: 10.5414/CN107244. Clin Nephrol. 2012. PMID: 22257542
Cited by
-
Omega-3 supplements in the prevention and treatment of youth depression and anxiety symptoms: A scoping review.PLoS One. 2023 Apr 20;18(4):e0284057. doi: 10.1371/journal.pone.0284057. eCollection 2023. PLoS One. 2023. PMID: 37079580 Free PMC article.
-
Toward prevention of bipolar disorder in at-risk children: Potential strategies ahead of the data.J Affect Disord. 2020 Jul 1;272:508-520. doi: 10.1016/j.jad.2020.03.025. Epub 2020 Mar 6. J Affect Disord. 2020. PMID: 32553395 Free PMC article. Review.
-
A Randomized, Double-Blind, Controlled Clinical Trial of Omega-3 Fatty Acids and Inositol as Monotherapies and in Combination for the Treatment of Pediatric Bipolar Spectrum Disorder in Children Age 5-12.Psychopharmacol Bull. 2022 Oct 27;52(4):31-51. Psychopharmacol Bull. 2022. PMID: 36339275 Free PMC article. Clinical Trial.
-
Omega-3 fatty acid supplementation for depression in children and adolescents.Cochrane Database Syst Rev. 2024 Nov 20;11(11):CD014803. doi: 10.1002/14651858.CD014803.pub2. Cochrane Database Syst Rev. 2024. PMID: 39564892
-
Importance of EPA and DHA Blood Levels in Brain Structure and Function.Nutrients. 2021 Mar 25;13(4):1074. doi: 10.3390/nu13041074. Nutrients. 2021. PMID: 33806218 Free PMC article. Review.
References
-
- Marcus M, Yasamy MT, Ommeren MV, Van Ommeren M, Chisholm D, Saxena S, et al. Depression: a global public health concern. Geneva: World Health Organization, Department of Mental Health and Substance Abuse; 2012.
-
- Costello JE, Erkanli A, Angold A. Is there an epidemic of child or adolescent depression? J Child Psychol Psychiatry. 2006;47:1263–1271. - PubMed
LinkOut - more resources
Full Text Sources